Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task

References

• Goldberg MS. Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer. 2019;19:587–602. doi:10.1038/s41568-019-0186-9.
   PubMed Web of Science ®Google Scholar
• Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Next-generation regulatory T cell therapy. Nat Rev Drug Discov. 2019;18:749–69. doi:10.1038/s41573-019-0041-4.
   PubMed Web of Science ®Google Scholar
• Sponghini A, Patrucco F, Giorgione R, Farinelli P, Zottarelli F, Rondonotti D, Savoia P. Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma: efficacy and tolerability in an elderly patient. Anticancer Drugs. 2017;28:808–10. doi:10.1097/CAD.0000000000000515.
   PubMed Web of Science ®Google Scholar
• Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18:e731–e741. doi:10.1016/S1470-2045(17)30607-1.
   PubMed Web of Science ®Google Scholar
• Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol. 2019;19:665–74. doi:10.1038/s41577-019-0221-9.
   PubMed Web of Science ®Google Scholar
• Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med. 2016;22:230–41. doi:10.1016/j.molmed.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Caporali R, Crepaldi G, Codullo V, Benaglio F, Monti S, Todoerti M, Montecucco C. 20 years of experience with tumour necrosis factor inhibitors: what have we learned?. Rheumatology (Oxford). 2018;57:vii5–vii10. doi:10.1093/rheumatology/key059.
   PubMed Web of Science ®Google Scholar
• Dhupkar P, Gordon N. Interleukin-2: old and new approaches to enhance immune-therapeutic efficacy. Adv Exp Med Biol. 2017;995:33–51.
   PubMed Web of Science ®Google Scholar
• Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71–109. doi:10.1146/annurev-immunol-031210-101312.
   PubMed Web of Science ®Google Scholar
• Ni G, Wang T, Walton S, Zhu B, Chen S, Wu X, Wang Y, Wei MQ, Liu X. Manipulating IL-10 signalling blockade for better immunotherapy. Cell Immunol. 2015;293:126–29. doi:10.1016/j.cellimm.2014.12.012.
   PubMed Web of Science ®Google Scholar
• Wang X, Wong K, Ouyang W, Rutz S. Targeting IL-10 family cytokines for the treatment of human diseases. Cold Spring Harb Perspect Biol. 2019;11:a028548. doi:10.1101/cshperspect.a028548.
   PubMed Web of Science ®Google Scholar
• Ouyang W, O’Garra A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity. 2019;50:871–91. doi:10.1016/j.immuni.2019.03.020.
   PubMed Web of Science ®Google Scholar
• Llopiz D, Ruiz M, Silva L, Sarobe P. Enhancement of antitumor vaccination by targeting dendritic cell-related IL-10. Front Immunol. 2018;9:1923. doi:10.3389/fimmu.2018.01923.
   PubMed Web of Science ®Google Scholar
• Gabrysova L, Howes A, Saraiva M, O’Garra A. The regulation of IL-10 expression. Curr Top Microbiol Immunol. 2014;380:157–90. doi:10.1007/978-3-662-43492-5_8.
   PubMed Web of Science ®Google Scholar
• Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10:170–81. doi:10.1038/nri2711.
   PubMed Web of Science ®Google Scholar
• O’Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev. 2008;223:114–31. doi:10.1111/imr.2008.223.issue-1.
   PubMed Web of Science ®Google Scholar
• Saraiva M, Vieira P, O’Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2020;217. doi:10.1084/jem.20190418.
   PubMed Web of Science ®Google Scholar
• Brooks DG, Lee AM, Elsaesser H, McGavern DB, Oldstone MB. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med. 2008;205:533–41. doi:10.1084/jem.20071948.
   PubMed Web of Science ®Google Scholar
• Chen S, Ni G, Wu X, Zhu B, Liao Z, Wang Y, Liu X. Blocking IL-10 signalling at the time of immunization renders the tumour more accessible to T cell infiltration in mice. Cell Immunol. 2016;300:9–17. doi:10.1016/j.cellimm.2015.11.002.
   PubMed Web of Science ®Google Scholar
• Liu XS, Leerberg J, MacDonald K, Leggatt GR, Frazer IH. IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. J Immunol. 2009;183:51–58. doi:10.4049/jimmunol.0802047.
   PubMed Web of Science ®Google Scholar
• Silva JR, Sales NS, Silva MO, Aps L, Moreno ACR, Rodrigues EG, Ferreira LCS, Diniz MO. Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model. Cancer Immunol Immunother. 2019;68:753–63. doi:10.1007/s00262-018-02297-2.
   PubMed Web of Science ®Google Scholar
• Ni G, Wang Y, Cummins S, Walton S, Mounsey K, Liu X, Wei MQ, Wang T. Inhibitory mechanism of peptides with a repeating hydrophobic and hydrophilic residue pattern on interleukin-10. Hum Vaccin Immunother. 2017;13:518–527. doi:10.1080/21645515.2016.1238537.
   PubMed Web of Science ®Google Scholar
• Berezhnoy A, Stewart CA, McNamara JO 2nd, Thiel W, Giangrande P, Trinchieri G, Gilboa E. Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing. Mol Ther. 2012;20:1242–50. doi:10.1038/mt.2012.18.
   PubMed Web of Science ®Google Scholar
• Chen S, Wang X, Wu X, Wei MQ, Zhang B, Liu X, Wang Y. IL-10 signalling blockade at the time of immunization inhibits human papillomavirus 16 E7 transformed TC-1 tumour cells growth in mice. Cell Immunol. 2014;290:145–51. doi:10.1016/j.cellimm.2014.06.002.
   PubMed Web of Science ®Google Scholar
• Pan X, Ma B, You X, Chen S, Wu J, Wang T, Walton SF, Yuan J, Wu X, Chen G, et al. Synthesized natural peptides from amphibian skin secretions increase the efficacy of a therapeutic vaccine by recruiting more T cells to the tumour site. BMC Complement Altern Med. 2019;19:163. doi:10.1186/s12906-019-2571-z.
   PubMed Web of Science ®Google Scholar
• Llopiz D, Aranda F, Diaz-Valdes N, Ruiz M, Infante S, Belsue V, Lasarte JJ, Sarobe P. Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination. Oncoimmunology. 2016;5:e1075113. doi:10.1080/2162402X.2015.1075113.
   PubMed Web of Science ®Google Scholar
• Brooks DG, Ha SJ, Elsaesser H, Sharpe AH, Freeman GJ, Oldstone MB. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A. 2008;105:20428–33. doi:10.1073/pnas.0811139106.
   PubMed Web of Science ®Google Scholar
• Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol. 2000;165:2783–89. doi:10.4049/jimmunol.165.5.2783.
   PubMed Web of Science ®Google Scholar
• Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, et al. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol. 2016;34:3562–69. doi:10.1200/JCO.2016.68.1106.
   PubMed Web of Science ®Google Scholar
• Frydenlund N, Mahalingam M. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. Hum Pathol. 2017;66:13–33. doi:10.1016/j.humpath.2017.06.012.
   PubMed Web of Science ®Google Scholar
• Ha SJ, West EE, Araki K, Smith KA, Ahmed R. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev. 2008;223:317–33. doi:10.1111/j.1600-065X.2008.00638.x.
   PubMed Web of Science ®Google Scholar
• Sun Z, Fourcade J, Pagliano O, Chauvin JM, Sander C, Kirkwood JM, Zarour HM. IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells. Cancer Res. 2015;75:1635–44. doi:10.1158/0008-5472.CAN-14-3016.
   PubMed Web of Science ®Google Scholar
• Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ, et al. IL10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res. 2017;77:6667–78. doi:10.1158/0008-5472.CAN-17-0740.
   PubMed Web of Science ®Google Scholar
• Chandra J, Dutton JL, Li B, Woo WP, Xu Y, Tolley LK, Yong M, Wells JW, RL G, Finlayson N, et al. DNA vaccine encoding HPV16 oncogenes E6 and E7 induces potent cell-mediated and humoral immunity which protects in tumor challenge and drives E7-expressing skin graft rejection. J Immunother. 2017;40:62–70. doi:10.1097/CJI.0000000000000156.
   PubMed Web of Science ®Google Scholar
• Qiao J, Liu Z, Dong C, Luan Y, Zhang A, Moore C, Fu K, Peng J, Wang Y, Ren Z, et al. Targeting tumors with IL-10 prevents dendritic cell-mediated CD8(+) T cell apoptosis. Cancer Cell. 2019;35:901–915 e904. doi:10.1016/j.ccell.2019.05.005.
   PubMed Web of Science ®Google Scholar
• Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019;20:1544–55. doi:10.1016/S1470-2045(19)30514-5.
   PubMed Web of Science ®Google Scholar
• Takeda K, Nakayama M, Hayakawa Y, Kojima Y, Ikeda H, Imai N, Ogasawara K, Okumura K, Thomas DM, Smyth MJ. IFN-gamma is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat Commun. 2017;8:14607. doi:10.1038/ncomms14607.
   PubMed Web of Science ®Google Scholar
• Llopiz D, Ruiz M, Infante S, Villanueva L, Silva L, Hervas-Stubbs S, Alignani D, Guruceaga E, Lasarte JJ, Sarobe P. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. Oncotarget. 2017;8:2659–71. doi:10.18632/oncotarget.v8i2.
   PubMedGoogle Scholar
• Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med. 2002;196:541–49. doi:10.1084/jem.20020732.
   PubMed Web of Science ®Google Scholar
• Liu XS, Dyer J, Leggatt GR, Fernando GJ, Zhong J, Thomas R, Frazer IH. Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host. J Immunol. 2006;177:2873–79. doi:10.4049/jimmunol.177.5.2873.
   PubMed Web of Science ®Google Scholar
• Shen L, Li J, Liu Q, Song W, Zhang X, Tiruthani K, Hu H, Das M, Goodwin TJ, Liu R, et al. Local blockade of interleukin 10 and C-X-C motif chemokine ligand 12 with nano-delivery promotes antitumor response in murine cancers. ACS Nano. 2018;12:9830–41. doi:10.1021/acsnano.8b00967.
   PubMed Web of Science ®Google Scholar
• Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J, et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell. 2011;20:781–96. doi:10.1016/j.ccr.2011.11.003.
   PubMed Web of Science ®Google Scholar
• Ni G, Chen S, Yang Y, Cummins SF, Zhan J, Li Z, Zhu B, Mounsey K, Walton S, Wei MQ, et al. Investigation the possibility of using peptides with a helical repeating pattern of hydro-phobic and hydrophilic residues to inhibit IL-10. PLoS One. 2016;11:e0153939. doi:10.1371/journal.pone.0153939.
   PubMed Web of Science ®Google Scholar
• Mumm JB, Oft M. Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-gamma-mediated CD8(+) T cell cytotoxicity. Bioessays. 2013;35:623–31. doi:10.1002/bies.201300004.
   PubMedGoogle Scholar
• Chan IH, Wu V, McCauley S, Grimm EA, Mumm JB. IL-10: expanding the immune oncology horizon. Recept Clin Invest. 2015;2:1041.
   PubMedGoogle Scholar
• Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A, Sahebkar A. PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol. 2019;234:16824–37. doi:10.1002/jcp.28358.
   PubMed Web of Science ®Google Scholar
• Walter MR. The molecular basis of IL-10 function: from receptor structure to the onset of signaling. Curr Top Microbiol Immunol. 2014;380:191–212. doi:10.1007/978-3-662-43492-5_9.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–98. doi:10.1038/ni1102-991.
   PubMed Web of Science ®Google Scholar
• Gasser S, Lim LHK, Cheung FSG. The role of the tumour microenvironment in immunotherapy. Endocr Relat Cancer. 2017;24:T283–T295. doi:10.1530/ERC-17-0146.
   PubMed Web of Science ®Google Scholar
• Ye Z, Huang H, Hao S, Xu S, Yu H, Van Den Hurk S, Xiang J. IL-10 has a distinct immunoregulatory effect on naive and active T cell subsets. J Interferon Cytokine Res. 2007;27:1031–38. doi:10.1089/jir.2006.0144.
   PubMed Web of Science ®Google Scholar
• Rennick DM, Fort MM, Davidson NJ. Studies with IL-10-/- mice: an overview. J Leukoc Biol. 1997;61:389–96. doi:10.1002/jlb.1997.61.issue-4.
   PubMed Web of Science ®Google Scholar
• Ni G, Liao Z, Chen S, Wang T, Yuan J, Pan X, Mounsey K, Cavezza S, Liu X, Wei MQ. Blocking IL-10 signalling at the time of immunization does not increase unwanted side effects in mice. BMC Immunol. 2017;18:40. doi:10.1186/s12865-017-0224-x.
   PubMed Web of Science ®Google Scholar
• Autio K, Oft M. Pegylated interleukin-10: clinical development of an immunoregulatory cytokine for use in cancer therapeutics. Curr Oncol Rep. 2019;21:19. doi:10.1007/s11912-019-0760-z.
   PubMed Web of Science ®Google Scholar
• Soncin I, Sheng J, Chen Q, Foo S, Duan K, Lum J, Poidinger M, Zolezzi F, Karjalainen K, Ruedl C. The tumour microenvironment creates a niche for the self-renewal of tumour-promoting macrophages in colon adenoma. Nat Commun. 2018;9:582. doi:10.1038/s41467-018-02834-8.
   PubMed Web of Science ®Google Scholar
• Nielsen SR, Schmid MC. Macrophages as key drivers of cancer progression and metastasis. Mediators Inflamm. 2017;2017:9624760. doi:10.1155/2017/9624760.
   PubMed Web of Science ®Google Scholar
• Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017;356:513–19. doi:10.1126/science.aal3535.
   PubMed Web of Science ®Google Scholar
• Chan IH, Wu V, Bilardello M, Jorgenson B, Bal H, McCauley S, Van Vlasselaer P, Mumm JB. PEG-rIL-10 treatment decreases FoxP3(+) tregs despite upregulation of intratumoral IDO. Oncoimmunology. 2016;5:e1197458. doi:10.1080/2162402X.2016.1197458.
   PubMed Web of Science ®Google Scholar
• Ni G, Chen S, Yuan J, Cavezza SF, Wei MQ, Li H, Pan X, Liu X, Wang T. Comparative proteomic study reveals the enhanced immune response with the blockade of interleukin 10 with anti-IL-10 and anti-IL-10 receptor antibodies in human U937 cells. PLoS One. 2019;14:e0213813. doi:10.1371/journal.pone.0213813.
   PubMed Web of Science ®Google Scholar
• Wu T, Wu X, Wang HY, Chen L. Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer. Cancer Commun (London). 2019;39:21. doi:10.1186/s40880-019-0365-9.
   PubMed Web of Science ®Google Scholar